title: [Management of febrile neutropenia].
abstract: Febrile neutropenia is a severe complication of systemic chemotherapy and has a negative effect on morbidity, mortality and prognosis. It is usually caused by bacterial infection. Therefore patients at high risk should prophylactically be given GCSF and a fluoroquinolone. In most cases neutropenic fever requires hospitalization and immediate empiric antibiotic therapy following baseline diagnostics. If there is no improvement after 72-96 h, therapy should be modified and further tests initiated. In these cases fungal or viral infection should be considered.
authors.affiliation: Abteilung für Urologie, Kinderurologie und Uro-Onkologie, St. Josef-Hospital, Hospitalstraße 45, 53840 Troisdorf, Deutschland. norbert.rolfes@josef-hospital.de
authors.forename: N
authors.initials: N
authors.lastname: Rolfes
authors.forename: G
authors.initials: G
authors.lastname: Lümmen
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000139:chemically induced* / Q000188:drug therapy; D003937:Diagnosis, Differential; D024901:Drug Resistance, Multiple, Bacterial; D005335:Fever of Unknown Origin / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D009181:Mycoses / Q000139:chemically induced / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000188:drug therapy; D014565:Urogenital Neoplasms / Q000188:drug therapy*; D014777:Virus Diseases / Q000139:chemically induced / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents